PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc., (NASDAQ:ADXS)(NASDAQ:ADXSW), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that the first patient has been dosed in REALISTIC, a Phase 1 study being funded by Cancer Research UK (CRUK) to investigate the use of ADXS-HPV for the treatment of HPV-positive head and neck cancer.
Help employers find you! Check out all the jobs and post your resume.
